文章名稱引用次數

• Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib24
• Targeting Toll-Like Receptors for Cancer Therapy23
• PARP Inhibition in Cancer: An Update on Clinical Development22
• Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System22
• Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions17
• Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations14
• Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease14
• TRK Inhibition: A New Tumor-Agnostic Treatment Strategy14
• Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial12
• Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib11